Press Release: PARP Inhibitor Olaparib for Breast Cancer
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
AstraZeneca announced that in an international, multi-center Phase 3 clinical trial involving patients with HER2-negative metastatic breast cancer carrying BRCA1 or BRCA2 mutations, the PARP inhibitor Olaparib met its primary endpoint. This demonstrates that the drug is effective not only for ovarian cancer but also for breast cancer. The trial is named OLYMPIAD, and further information can be found online.
The OLYMPIAD trial focused on patients with metastatic breast cancer who had received prior treatments, such as anthracyclines or taxanes, or as adjuvant therapy after surgery. This drug has also undergone clinical trials in Japan.
As mentioned, this Phase 3 trial compared patients receiving Olaparib (300 mg twice daily) with a physician-selected treatment group (receiving either capecitabine, eribulin, or vinorelbine). Eligibility criteria included prior treatment with anthracyclines or taxanes for metastatic breast cancer, or as adjuvant therapy, or endocrine therapy for hormone receptor-positive patients.
The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), second progression-free survival (PFS2), and health-related quality of life (HRQoL). Crucially, the trial results showed superior outcomes for the Olaparib group. Detailed findings will be fully presented at upcoming medical conferences. Currently, AstraZeneca is also conducting Phase 3 trials targeting patients with non-metastatic breast cancer.
For the related press release, please refer to: https://www.astrazeneca.com/media-centre/press-releases/2017/lynparza-meets-primary-endpoint-in-phase-iii-trial-in-brca-mutated-metastatic-breast-cancer-17022017.html
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4